Anchor Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Anchor Therapeutics's estimated annual revenue is currently $1.4M per year.
- Anchor Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Anchor Therapeutics has 9 Employees.
- Anchor Therapeutics grew their employee count by 0% last year.
Anchor Therapeutics's People
| Name | Title | Email/Phone |
|---|
Anchor Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.7M | 82 | -45% | $107.3M | N/A |
#2 | $0.2M | 1 | -50% | N/A | N/A |
#3 | $6.2M | 40 | 21% | N/A | N/A |
#4 | $42.2M | 218 | 4% | $165M | N/A |
#5 | $14.6M | 94 | -37% | $312.8M | N/A |
#6 | $0.3M | 2 | -67% | N/A | N/A |
#7 | $235M | 366 | -5% | $340.9M | N/A |
#8 | $56M | 289 | -7% | $7.6M | N/A |
#9 | $4.7M | 61 | 36% | N/A | N/A |
#10 | $2M | 13 | 8% | N/A | N/A |
What Is Anchor Therapeutics?
Anchor Therapeutics is pioneering a new class of drugs called Pepducins. Pepducins are a breakthrough approach to targeting and allosterically modulating G-protein coupled receptors (GPCRs) on the inside surface of the cell membrane. GPCRs are critically involved in a wide variety of serious illnesses, including diabetes, inflammation, cancer, CNS disorders and cardiovascular disease. Pepducin technology represents an exciting new area of research directed towards a well-validated class of drug targets including orphan and intractable targets.
keywords:N/A
N/A
Total Funding
9
Number of Employees
$1.4M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.7M | 9 | -40% | $132.1M |
#2 | $0.7M | 9 | N/A | N/A |
#3 | $0.7M | 9 | N/A | N/A |
#4 | $0.7M | 9 | -18% | $107M |
#5 | $0.7M | 9 | 0% | N/A |